Abstract
Programmed death-ligand 1 (PD-L1) expression in aUC has been studied extensively in clinical trials. In the DANUBE trial, 60% of patients (pts) with aUC had high tumor PD-L1 expression using the Ventana PD-L1 (SP263) Assay. As the first-line (1L) aUC therapy landscape keeps evolving, discovery and validation of biomarkers with the clinical utility to enable patient selection is important. In that context, there is a need to better understand testing practices and the prevalence of PD-L1 for patients with aUC in the real-world setting.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
